Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C12H13N3O4S |
| Molecular Weight | 295.314 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NC1=CC=C(C=C1)S(=O)(=O)NC2=NOC(C)=C2
InChI
InChIKey=GXPIUNZCALHVBA-UHFFFAOYSA-N
InChI=1S/C12H13N3O4S/c1-8-7-12(14-19-8)15-20(17,18)11-5-3-10(4-6-11)13-9(2)16/h3-7H,1-2H3,(H,13,16)(H,14,15)
| Molecular Formula | C12H13N3O4S |
| Molecular Weight | 295.314 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes. | 2005-07 |
|
| Metabolism by N-acetyltransferase 1 in vitro and in healthy volunteers: a prototype for targeted inhibition. | 2004-12 |
|
| Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4+ T cells from allergic individuals. | 2000-06-15 |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:52:55 GMT 2025
by
admin
on
Mon Mar 31 19:52:55 GMT 2025
|
| Record UNII |
3I1988834Q
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
65280
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
3I1988834Q
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL443
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
21312-10-7
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
31169
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
244-330-5
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
1631511
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
DTXSID8049044
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | |||
|
m10320
Created by
admin on Mon Mar 31 19:52:55 GMT 2025 , Edited by admin on Mon Mar 31 19:52:55 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> METABOLITE |
in slow
acetylators, more parent drug is shunted toward the
oxidative cytochrome P-450 pathway with the subsequent formation of the reactive hydroxylamine and nitroso metabolites. In a retrospective study, 90% of 21 patients
who suffered from sulfa allergy were slow acetylators
versus 55% in the general population, demonstrating an increased risk of ADRs to sulfonamides in slow acetylators.
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|